Journal article Open Access
Background: The therapeutic options in invasive candidiasis and aspergillosis are limited and don’t provide expected results. Introducing a new drug in the therapeutic practice can improve the quality of life of immunocompromised patients. The aim of this research is to study the antimycotic activity of new substance phenoxithiazolchloralum (MF-0010) on Aspergillus spp., Candida albicans, and Saccharomyces cerevisiae.
Material and methods: Phenoxythiazolchoralum has been kindly offered by the Institute of Chemistry. The standards were offered by Nicolae Testemitanu State University of Medicine and Pharmacy. Antifungal activity of the phenoxythiazolchloralum against Aspergillus spp. was evaluated by microdilution method. The successive double dilution method was used for determination of in vitro susceptibility against Candida albicans, and Saccharomyces cerevisiae.
Results: For the first time, it was studied in vitro susceptibility of MF-0010 against Aspergillus spp., Candida albicans, Saccharomyces cerevisiae. With at least 0.05 μM/ml difference of MF-0010 MIC value from standards, it can be considered quite more potent than ketoconazole and bifonazole against Aspergillus fumigatus, Aspergillus versicolor, Aspergillus ochramensis. The MIC/MCF ratios of MF-0010 are lower than nistatine ones with 0.08 μMol for both pathogens: Candida albicans, and Saccharomyces cerevisiae.
Conclusions: All analyzed pathogens were susceptible to MF-0010. According to experimental data on Aspergillus spp., the antimycotic activity of MF-0010 is quite better than the standards one. The MIC/MCF ratios showed in vitro significant susceptibility of MF-0010 against Candida albicans.